

Regulatory Announcement

Company AKERS BIOSCIENCES INC
TIDM AKR
Headline United States Military Contract
Released 07:00 18-Sep-07

Embargoed: 0700hrs, 18 September 2007

Akers Biosciences, Inc

('ABI' or the 'Company')

Receipt of Further United States Military Contracts

Further to yesterday's announcement that the United States Army had placed an order for \$2,500,000 of BreathScan alcohol safety units, ABI is pleased to announce that the United States Navy has today placed orders for the same products valued at \$2,000,000, deliverable in shipments beginning immediately and continuing through 2007.

ABI develops, manufactures, and supplies rapid, point of care screening and testing products and has been catering for the demand from several departments of the United States Government as a result of its efforts to increase safety awareness. The units provided consist of the Company's unique, patented disposable breathalyzer device housed within its patented, portable and refillable key ring case.

Thomas A. Nicolette, President and Chief Financial Officer of ABI, commented,

'This latest order will take the total number of our BreathScan alcohol safety units in use by the US Military to over 1,500,000. This provides a basis for a recurring revenue business model generated from this product line as the key ring cases will require refill once the alcohol breathalyzers are used and disposed.

We are proud that our BreathScan alcohol safety units are currently in use by the United States Special Operation Command, the United States Army and now the Navy.'

Enquiries:

Akers Biosciences, Inc.

Thomas A. Nicolette, President & CFO

Tel. 001 856 848 8698

Hansard Group

Ben Simons

Tel. 020 7245 1100

Akers Biosciences

Akers Biosciences, Inc. develops, manufactures, and supplies rapid, point of care screening and testing products designed to bring healthcare information both rapidly and directly to the patient or healthcare provider. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The company's state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. Akers has aligned with major healthcare companies and high volume medical products distributors to maximize product offerings, and to be a major worldwide competitor in diagnostics. Additional information on the Company and its products can be found at www.akersbiosciences.com.

END